Special Issue "Natural and Artificial Vesicles and Nanoparticles against Brain Diseases"
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 14729
2. Istituto per la Ricerca e l’Innovazione Biomedica (IRIB), CNR, Via U. La Malfa 153, 90146 Palermo, Italy
Interests: neurodegeneration; mitochondrial dysfunction and oxidative stress; mitochondrial transplantation; nanotechnology and brain drug delivery systems; vesicles; immunotolerance and immunomodulation in multiple sclerosis
Special Issues, Collections and Topics in MDPI journals
Brain diseases (BD) affect millions of people around the world. These pathologies (inflammatory, trauma, tumors, stroke and neurodegenerative disease) represent a considerable global social and economic burden and constitute an unquestionable emergency, and a grand challenge for neuroscientists. The presence of various physiological barriers limits accessibility to the brain and reduces the effectiveness of various therapies. Furthermore, the improvement of the solubility, stability and release of the drugs/molecules in specific brain regions and in particular target cells are essential factors in developing an effective therapy. Several studies have reported that extracellular vesicles (EVs) are released from cells of the central nervous system (CNS), playing a significant role in its functions. Indeed, EVs are involved in the control of neurogenesis, in the regulation of the biogenesis of myelin sheaths and in the repair of damaged neurons. For these effects, VEs can be used for therapeutic purposes or as brain drug delivery systems (BDDS). Furthermore, recently artificial nanovesicles, such as cell membrane-based systems, and nanoparticles (NP) have received increasing interest as BDDS to counter BD. EVs, artificial nanovesicles and NP can target a CNS cell-type in specific regions of the brain. In conclusion, EVs, artificial nanovesicles and NP, thanks to their capacities, may represent a promising strategy against BD. Therefore, authors are invited to present original research articles, review papers or communications focused on the EVs and artificial nanovesicles as therapeutic tools to contrast BD.
Dr. Pasquale Picone
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- brain diseases
- extracellular vesicles
- artificial nanovesicles
- brain drug delivery systems
- cell target
- nanoparticles (NP)